IDEAYA Biosciences (IDYA) Stock Analysis & Winston Score

IDEAYA Biosciences is a clinical-stage biotechnology company focused on developing cancer treatments. It discovers and tests drugs that target specific genetic weaknesses in tumor cells, a strategy called synthetic lethality. Its main customers are cancer patients, and it works closely with larger pharmaceutical companies — most notably GlaxoSmithKline — through research partnerships. IDEAYA makes money primarily through collaboration agreements and milestone payments from partners rather than product sales, since it has no approved drugs yet. It operates mainly in the United States and had a market cap of roughly $3.4 billion as of mid-2026. Its lead drug candidate, darovasertib, targets a rare eye cancer called uveal melanoma, and the partnership with GSK provides funding and development resources that smaller biotechs typically lack. The key risk is that clinical trials can fail, and without an approved product generating revenue, the company depends on continued partnership funding and capital raises to stay operational.